{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:06:23Z","timestamp":1792008383682,"version":"4.4.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T00:00:00Z","timestamp":1382313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2014,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Haloperidol and pimozide are the only drugs currently approved by the U.S. Food and Drug Administration for treatment of Tourette syndrome (TS), but their potential side effects, which include tardive dyskinesia (TD), limit their use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a retrospective chart review of patients with TS treated with fluphenazine over a 26\u2010year period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 268 patients with TS, fluphenazine was initiated at a mean age of 15.8\u2009\u00b1\u200910.7 years (range, 4.1\u201370.2) and titrated to an optimal dose of 3.24\u2009\u00b1\u20092.3 mg\/day (range, 0.5\u201312.0), which was continued for an average of 2.6\u2009\u00b1\u20093.2 years (range, 0.01\u201316.8). Marked to moderate improvement was noted in 211 (80.5%). The most common side effects included drowsiness, fatigue, or both, observed in 70 (26.1%) patients. There were no cases of TD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Fluphenazine appears to be safe and effective in the treatment of TS, and there were no cases of TD in this cohort treated up to 16.8 years. \u00a9 2013 International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.25692","type":"journal-article","created":{"date-parts":[[2013,10,21]],"date-time":"2013-10-21T11:55:53Z","timestamp":1382356553000},"page":"126-130","source":"Crossref","is-referenced-by-count":59,"title":["Long\u2010term efficacy and safety of fluphenazine in patients with Tourette syndrome"],"prefix":"10.1002","volume":"29","author":[{"given":"Subhashie","family":"Wijemanne","sequence":"first","affiliation":[{"name":"Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.C.","family":"Wu","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[{"name":"Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,10,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra010032"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23618"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2008.03.006"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2012.26"},{"key":"e_1_2_7_6_1","first-page":"578","article-title":"A case of tic of Gilles de la Tourette cured by R 1625. [Article in French]","volume":"119","author":"Seignot JN","year":"1961","journal-title":"Ann Med Psychol (Paris)"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.114.508.345"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.8.1057"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1989.01810080052006"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-198403000-00007"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0887-8994(85)90063-3"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.1993.3.137"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0361-9230(83)90192-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000120222"},{"key":"e_1_2_7_15_1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders TE, Revised (DSM\u2010III\u2010R)","author":"American Psychiatric Association","year":"1987"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1993.00540100012008"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1984.04050150049015"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.152.5.765"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbp116"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870040208"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4377-2369-4.00019-6"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.937"},{"key":"e_1_2_7_23_1","first-page":"254","article-title":"Integrating incidence and prevalence of tardive dyskinesia","volume":"22","author":"Kane JM","year":"1986","journal-title":"Psychopharmacol Bull"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0913"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23894"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870030313"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1982.04290040069010"},{"key":"e_1_2_7_28_1","article-title":"An update on tardive dyskinesia: from phenomenology to treatment","volume":"3","author":"Waln O","year":"2013","journal-title":"Tremor Other Hyperkinet Mov"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1586\/ern.10.58"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199300810-00003"},{"key":"e_1_2_7_31_1","first-page":"451","article-title":"Neuroleptics and extrapyramidal reactions in psychiatric patients","volume":"20","author":"Ayd FJ","year":"1961","journal-title":"Rev Can Biol"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.132.5.532"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00178501"},{"key":"e_1_2_7_34_1","first-page":"CD006352","article-title":"Oral fluphenazine versus placebo for schizophrenia","author":"Matar HE","year":"2007","journal-title":"Cochrane Database Syst Rev."},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23402"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25692","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.25692","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.25692","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T11:10:19Z","timestamp":1760958619000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.25692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,21]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["10.1002\/mds.25692"],"URL":"https:\/\/doi.org\/10.1002\/mds.25692","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,21]]}}}